Targeting Mitochondrial Dysfunction & Toxicity Conference March 19-10, 2014 | Boston, MA Mitochondrial dysfunction has been identified as an important factor in diseases ranging from neurodegenerative conditions (ALS, Alzheimer’s, Parkinson’s Disease)

Driven by the rapid development of the biopharmaceuticals market in China, the demand for high-quality biotherapeutic proteins is higher than ever.

In this DVD, we will provide a baseline understanding of the regulatory need, common practices and real world examples of integrating Human Factors Engineering into a drug development activity. Key topics to be addressed: Why you should care: Regulatory expectations for the application of HFE What to avoid: Right and wrong ways to apply HFE to your project Lessons from the field: Real world examples of HFE

This course will address the questions on “why should I care about kinetics?” and “how can I understand and predict Structure-Kinetics relationships?” We will first review the role of binding kinetics in drug action and then focus on the particular case of protein-ligand non-covalent complexes, reviewing what is known so far about the structural determinants of binding kinetics. This course will help you with a better understanding and increased awareness of current state of the chemistry and pharmacology of binding kinetics.

The advancing technology of high-throughput screening is changing the type of molecules found. With protein function more physiologically relevant, the quality of the molecules that pharmacologists and medicinal chemists must deal with is changing. This course will familiarize researchers with the tools needed to exploit this potentially fruitful area of new drug discovery through discussion of allosteric molecules, detection of allosterism, and quantifying allosterism for chemical lead optimization.